EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study

All NewsMay 6, 2026

Medicus Pharma reports dose-response in Phase 2 BCC study, with 200µg cohort showing the strongest efficacy and safety profile at Day 57.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent